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Abstract
Objective. To evaluate the cost–utility of different treatment strategies in severe RA after TNF-inhibitor
failure.
Methods. The cost-effectiveness of treatment strategies was compared in a group of hypothetical Finnish
RA patients. Initially, the patients received either best supportive care (BSC) or one of the following
treatments before BSC: adalimumab (ADAL), abatacept (ABAT), etanercept (ETAN), infliximab (INFL) or
rituximab (RTX). Further treatments were added to the most cost-effective strategy in a stepwise manner.
The analysis was performed on an Excel-based Markov state transition model using the probabilistic
approach. The clinical outcomes related to treatments were estimated from published clinical trials. The
gained quality-adjusted life-years (QALYs) were estimated based on Health Utilities Index (HUI-3) and
disease severity scores (HAQ). The resource use and costs were obtained from the Finnish treatment
practice, one published study, the Finnish Unit Cost list and Finnish Medicine Tariffs.
Results. Treatment with RTX was more effective and less costly than treatment with ADAL, ABAT or ETAN
after TNF-inhibitor failure. An additional QALY gained with RTX costs 30248 euros compared with BSC.
The incremental cost-effectiveness ratios (ICERs) are 50941, 50372, 36121 and 67 003 euros per QALY
gained for adding ADAL, ETAN, INFL and ABAT to the RTX strategy, respectively. According to the
cost-effectiveness acceptability frontier (CEAF), only BSC or treatments with RTX or RTX followed
by INFL should be considered after TNF-inhibitor failure, if willingness to pay is between 0 and
50000 euros per QALY gained.
Conclusions. Treatment with RTX is a cost-effective treatment strategy in RA patients in Finland.
Key words: Abatacept, Adalimumab, Cost-effectiveness analysis, Infliximab, Etanercept, Rheumatoid arthritis,
Rituximab, TNF-inhibitor.
Introduction
RA is a progressive, chronic, systemic autoimmune disor-
der that has the potential to cause joint destruction and
functional disability. RA decreases the patient’s quality of
life (QoL) significantly. Based on a recent publication [1],
the annual quality-adjusted life years lost (QALYs-loss)
due to RA has been estimated to be 2.69 QALYs per
1000 people (using EQ-5D) in Finland. RA is associated
with an increased risk of death, and the life expectancy for
RA patients has been 3–4 years shorter than in the general
population [2]. The prevalence of RA is  0.8% in Finland
[3].
The treatment of RA in Finland is aimed at remission of
the disease and maintenance of normal functioning and
QoL [4]. Treatment is usually initiated with traditional
DMARDs (tDMARDs). According to statistics of pharma-
ceutical use in Finnish RA patients, the most commonly
prescribed tDMARDs in 2005 were MTX (20922 users),
SSZ (17718 users) and HCQ (14871). Gold products
(4752), LEF (3438 users), AZA (2252 users), CSA (1401
users) [5] and biologic treatments [3371 users of etaner-
cept (ETAN), anakinra and adalimumab (ADAL) in 2007;
2167 users in 2005] [6] (SII: Statistics on Medicine) were
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Eused less frequently; credible user data for infliximab
(INFL) could not be obtained.
Generally, rituximab (RTX) or abatacept (ABAT) is con-
sidered as an option for those RA patients who do not
tolerate or who do not get an adequate response to
other treatments, including at least one TNF-inhibitor ther-
apy. This study aims to evaluate the cost–utility of differ-
ent treatment strategies after treatment failure with one
TNF-inhibitor in a Finnish setting.
The treatment strategies considered in this evaluation
are initiated with another TNF-inhibitor (ETAN+MTX,
ADAL+MTX and INFL+MTX), ABAT+MTX or RTX+
MTX and their cost–utility is compared with the best sup-
portive care (BSC). For the study purposes, BSC is
defined as treatment with intramuscular gold followed by
CSA and MTX. When the biologic treatment fails, the
patients receive either BSC or they are further treated
with another biologic treatment before BSC. The cost-
effectiveness of these treatment strategies is estimated
step by step in order to evaluate the cost-effectiveness
of adding further treatments to these patients.
The model framework is consistent with the current
Finnish treatment practice, since the patients initiating
biologic treatments have usually already been treated
with tDMARDs (including combination with SSZ, MTX
and HCQ), LEF+MTX and either ETAN+MTX or
ADAL+MTX. The reason for favouring these injectable
TNF-inhibitor products over INFL infusions lies in the
Finnish health care financing system, where pharmaceu-
ticals given in hospitals are financed by municipalities and
pharmaceuticals purchased from pharmacies are
financed by the Social Security Institution of Finland. As
the municipalities face pressure to contain health care
costs, the use of INFL is discouraged. However, all
relevant treatment options after TNF-inhibitor failure are
assessed in this study to achieve international compar-
ability and to openly assess the current practice.
Methods
Model structure
The evaluation was performed on a Microsoft
Excel-based microsimulation Markov model [7], in which
the life-time treatment outcomes (i.e. life-time costs and
benefits) were simulated for identical, hypothetical RA
patient cohorts. The cohorts consist of 3000 patients
(which we assumed to be the number of potential RA
patients in Finland), 33% male and 67% female, with an
average age of 48 (S.D. 10) years [8] and an average HAQ
score of 1.9 (S.D. 0.58) at baseline [9]. The model is run
1000 times using the transition probabilities in Table 1 to
obtain probabilistic sensitivity analysis (PSA) results. The
modelling ends when the patients have turned 100 years
or died.
The cycle length of the model is 6 months and transi-
tions between health states can occur once every cycle.
After the first cycle, the response status of the patients is
evaluated and non-responders are switched on to the
next treatment in succession. The responders’ response
status is evaluated using the American College of
Rheumatology criteria (ACR20/ACR50/ACR70), after
which they continue the same treatment for a predefined
time period (Table 1). After this time period, the patients
are assumed to relapse, lose all benefits of treatment
(their condition returns to the same level as it was
before the treatment) and switch on to the next treatment.
TABLE 1 Average time on treatment and adjusted ACR response rates (transition probabilities)
Drug
Time on
treatment, years ACR20 ACR50 ACR70 No response Source
RTX+MTX 3.75
a 0.27 0.17 0.13 0.43 Cohen et al. [9]*
ETAN+MTX 2.50
b 0.29 0.22 0.14 0.35 Weinblatt et al. [16]*
ADAL+MTX 2.50
b 0.21 0.16 0.18 0.46 Keystone et al. [17]*
INFL+MTX 2.50
b 0.24 0.20 0.08 0.47 Maini et al. [18]*
ABAT+MTX 3.75
c 0.32 0.11 0.11 0.46 Genovese et al. [33]*
GOLD 2.00
d 0.17 0.04 0.01 0.78 Assumption
e
CSA 4.50
f 0.17 0.04 0.01 0.78 Assumption
MTX 0.17 0.04 0.01 0.78 Weighted average of the
studies marked with asterisk
aKeystone et al. [32] report that 48% of patients withdrew from RTX over four courses of treatment. It was assumed that five
courses of RTX were given (9 months apart) summing to 3.75 years. This figure is likely to be an underestimate, because it
includes patients who dropped out at the first cycle, i.e. actually belong to the non-responder group of our model.
bEstimated
based on the results shown in Fig. 2 of article by Duclos et al. [34]. Since the time on treatment in our study measures the time
on treatment for responders only, we increased the length of treatment by the proportion of patients who dropped out early (to
 33 months). Because the study also reported a hazard ratio of 2.17 for continuing the first compared with second treatment,
we took 2.5 years as an estimate for the treatment length.
cAssumed to be equal to RTX.
dBendix and Bjelle [35].
eAccording
to Hurst et al. [36], the efficacy of gold and MTX is similar ( 0.33 annualized HAQ area units for MTX compared with  0.38 for
gold).
fMedian use 75 months (6.25 years) in the study by Marra et al. [37]. On the other hand, in a study by Carpentier et al.
[38], the overall continuation rate was 50% after 36 months (3 years). Thus, 4.5 years is used.
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The model uses patients’ HAQ scores in the estimation of
the patient’s QoL [7, 10–12]. In the first cycle, the baseline
HAQ score (1.9) is assumed to change in response to
changes in the patients’ response status:  0.1,  0.45,
 0.85 and  1.11 for non-responders, ACR20, -50 and
-70, respectively [9]. After the first cycle, the patients’ con-
dition is assumed to deteriorate with time. The patient’s
HAQ score increases gradually by 0.065 for MTX [11] and
by 0.017 for all other treatments [13] every cycle. QoL is
estimated on the basis of the formula provided by
Bansback et al. [11]: QoL (HUI-3)=0.76 0.28 HAQ+
0.05 Female. QoL is extended at the patient level to
quality-adjusted survival measured as QALYs by multiply-
ing QoL with the time spent in the respective QoL.
Mortality
At every cycle of the model, the patients can die of natural
causes. The model applies an elevated mortality risk (RA
risk multiplier 1.33
HAQ [12]) to average Finnish life tables
[14] since the risk of death in RA patients is higher than in
the average population [2, 15].
Transition probabilities
The transition probabilities needed in the model are esti-
mated on the basis of response rates in the same manner
as was done in Kielhorn et al. [7]. The response rates
are taken from published randomized controlled clinical
trials [9,16–19] that reported the ACR response rates at 6
months and that had a common comparator treatment
(MTX) that enables indirect comparison of the efficacies
(an adjusted indirect comparison). The method
used for indirect comparison is presented in Appendix 1
(available as supplementary data at Rheumatology Online)
and the obtained transition probabilities are shown in
Table 1.
Resource use andcosts
The initiation of the first biologic treatment in Finland
necessitates a screening procedure (e.g. chest X-ray,
mantoux test and antibody tests) to evaluate the safety
of the initiation for the patients and an application for reim-
bursement status for pharmacy products. As the initiation
of another biologic treatment does not require the same
protocol, these costs are omitted from our model for all
products. However, it is assumed that patients need to
visit a specialized nurse to get instructions on how to
inject ADAL or ETAN also at the initiation of the second
injectable product.
All patients in the model are assumed to follow a stan-
dard protocol. The patients starting the treatment visit a
specialized physician [secondary care outpatient visit
(OPV)] at initiation and 3 and 6 months after initiation.
Thereafter, the OPVs are scheduled once every 6
months. In addition, the patients visit the general practi-
tioner on an average every 6 months. The laboratory
values of the patients during treatment are monitored at
the initiation of treatment, 1 and 3 months after the initia-
tion and every 3 months thereafter. The costs for health
care resources in this standard protocol are shown in
Table 2.
TABLE 2 Resource use and unit costs [22] in 2008
Resource Cost per visit, A Resource use (S.E.)
Nurse 41.80
a RTX, INFL, ABAT, CSA, MTX 0
ETAN, ADAL, first cycle 1
Intramuscular gold Every 4 weeks
Outpatient visit
(internal diseases)/day unit visit
190.62 First cycle 2
Later cycles 1
General practitioner visit
a 44.86 First cycle 0
Later cycles 1
Inpatient day (internal diseases),
cost/day
628.26 0.0<HAQ score <0.5 0.68 (0.07)
0.6<HAQ score <1.0 2.77 (0.28)
1.1<HAQ score <1.5 4.12 (0.41)
1.6<HAQ score <2.0 8.86 (0.89)
2.1<HAQ score <2.6 10.25 (1.03)
2.6<HAQ score <3.0 4.56 (0.46)
Phone consulting by patient
b 18.71 First cycle 1
Laboratory visit 4.81 First cycle 3
Laboratory tests (ESR, FBC, CRP,
liver function tests, creatinine and urea)
16.72 Later cycles 2
Travelling to primary health care (by patient) 6.48 –
c
Travelling to secondary health care (by patient) 33.13 –
c
aThe unit cost of outpatient visit in the primary health care for rheumatic diseases.
bThe laboratory results informed over phone
for the tests 1 month after initiation.
cNumber of journeys varies according to treatment. For example, RTX, ABAT and INFL
infusions are given in secondary care facilities, whereas ETAN and ADAL are not. If the infusion date is in the proximity of
scheduled OPV, the OPV is assumed to be on the date of the infusion and only one journey to secondary care is assumed.
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economical prices in the Finnish Medicine Tariff (11/2008)
estimated for an average patient (Table 3). The adminis-
tration cost for RTX, ABAT and INFL is assumed to be
equal to the cost of one OPV. This assumption is made
since the unit cost of an OPV includes most tests and
procedures related to those visits. In addition, one hospi-
tal district has given out a cost estimate of one visit at a
day unit (infusions in Finland are given in these units) of
170 euros, which is very close to the average unit cost of
an OPV. Since intramuscular gold is administered in the
primary health care by a nurse, an additional primary
health care visit is assumed to cover the administration
costs for gold. All patients are assumed to be able to inject
themselves with ETAN and ADAL.
The inpatient treatment is estimated on the basis of
HAQ score (Table 2), which reflects the disease severity.
The relationship between HAQ scores and inpatient days
in this study comes from a Swedish 5-year follow-up
study of 116 consecutive RA patients [10]. These
Swedish estimates are used since there is only very lim-
ited published information of this relationship for Finland.
A Finnish study by Laas et al. [20] reported that there were
altogether 395 inpatient days in a year for 96 patients who
had an average HAQ score of 1.37. This gives an average
number of inpatient days of 4.11, which is the same as in
the Swedish study [10].
Production losses due to RA are excluded from the
analysis, since patients with similar characteristics to our
patient population are usually retired in Finland. In a study
by Puolakka et al. [21], the yearly productivity losses were
on an average 22000 euros already at HAQ score 1 (aver-
age salary recommended for estimation of productivity
losses in Finland is 24309 euros [22]).
Analyses
Base-case analyses. The cost–utility of different treatment
alternatives is evaluated on the basis of the incremental
cost-effectiveness ratios (ICERs). Treatments are com-
pared in a stepwise manner: at first step, all alternative
treatments are compared with BSC and at subsequent
steps, other treatments are added to the treatment/
treatment sequence having the smallest ICER in the
previous step. The results are also depicted as the
cost-effectiveness efficiency frontier using a
cost-effectiveness plane.
Based on the probabilistic approach, the uncertainty
related to decision making is explored by presenting
a cost-effectiveness acceptability frontier (CEAF) [23].
In contrast to the conventional multinomial cost-
effectiveness acceptability curves (mCEAC) [23–25],
which presents the probability that a treatment is the
most cost-effective of all treatments at different willing-
ness to pay (WTP) per QALY gained levels, CEAF demon-
strates which of the treatments should be adopted
because it results in the highest expected net benefit for
a given WTP. This is related to the fact that in the case of
skewed distributions of net benefit, the treatment with the
highest probability of being cost-effective is not always
the treatment with the highest expected net benefit [26].
The net benefit is calculated conventionally as the total
cost minus the QALYs multiplied by the WTP.
All analyses are done from the Finnish societal perspec-
tive, in which the productivity losses are usually excluded.
All costs are estimated without VAT and adjusted to the
2008 price level using the health care price index pub-
lished by Statistics Finland (transformation coefficient for
year 2006: 1.0942). All costs and outcomes are dis-
counted by a 3% annual rate as recommended by the
Finnish authorities.
Sensitivity analyses. Multiple one-way sensitivity analyses
are performed to evaluate the effect of assumptions made
in the absence of conclusive data for some necessary
variables. In the sensitivity analyses, the values of the fol-
lowing variables are altered: average time period for treat-
ments (figures from Kielhorn et al. [7] used): 4.25 years for
RTX+MTX, ETAN+MTX, ADAL+MTX and ABAT+MTX
(ABAT+MTX was not assessed in Kielhorn et al. and we
therefore assumed the same length as for RTX+MTX);
TABLE 3 Therapeutic doses, treatment course and cost/dose
Therapy Dosage,
a mg Treatment course Cost/dose, A
RTX 1000
b Days 1 and 15; repeated every 9 months 3061.02
Methylprednisolone, intravenous 100
b 5.20
ETAN 50 One per week 295.19
ADAL 40 One per fortnight 618.71
INFL 210
b Days 1 and 2, and 6 weeks after the
first infusion. Thereafter, every 8 weeks
(3–10 mg/kg for 70-kg patient)
1306.62
ABAT 750
b Days 1, 15 and 29; repeated every 4 weeks 1116.00
Intramuscular gold 50
b Every (2–)4 weeks 5.06
CSA 210 Daily (2.5–)3 mg/kg, max 5 mg/kg 9.54
MTX 15 One per week 1.32
aThe dosages are obtained from Korpela [4].
bThe price of these products is the wholesale price; for pharmacy products the
pharmacy price (excluding VAT 8%) is used.
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for gold, length of RTX treatment cycle (6 months;
12 months), HAQ score—resource use relationship (inpa-
tient days 4.11 regardless of HAQ; 10% increase in
inpatient days for HAQ>1.6), QoL estimates (negative
QALYs allowed; QALYs estimated with [27]: QoL
(EQ-5D)=0.86 0.20 HAQ) and discount rate (0%).
Because the costs of outpatient (retail prices) and inpa-
tient (wholesale prices) pharmaceuticals differ significantly
in the Finnish system, we also report a sensitivity analysis
using the wholesale prices for ETAN (251.80 euros/dose)
and ADAL (543.77 euros/dose) to improve the interna-
tional generalization of the results.
Results
Base-case analyses
The results of the base-case analyses are shown in
Table 4 and Fig. 1. When the patients are given only
BSC for their RA, the average total treatment costs,
according to our model, are 85714 euros and the patients
gain on an average 2.69 QALYs during their remaining
FIG.1The cost-effectiveness efficiency frontier (CEEF) represents the most efficient choices among the compared
treatment strategies. The average costs and QALYs gained with BSC are given in the origin.








ICER vs the smallest ICER
in the previous scenario
0 BSC 85714 2.69
1 RTX!BSC 106921 3.39 30248
ADAL!BSC 111195 3.19 50941
ETAN!BSC 112546 3.22 50372
INFL!BSC 102558 3.15 36121
ABAT!BSC 127580 3.31 67003
2 RTX!ADAL!BSC 128053 3.79 38235 52021
a
RTX!ETAN!BSC 130258 3.83 38938 52698
a
RTX!INFL!BSC 120946 3.77 32621 37013
a
RTX!ABAT!BSC 142335 3.91 46367 68100
a
3 RTX!INFL!ADAL!BSC 141541 4.14 38329 54701
b
RTX!INFL!ETAN!BSC 143686 4.18 38785 54836
b
RTX!INFL!ABAT!BSC 155493 4.26 44466 70616
b
aCompared with RTX+MTX!BSC in scenario 1.
bCompared with RTX+MTX!INFL+MTX!BSC in scenario 2.
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efficient choices (and their respective ICERs) among the
compared treatment alternatives: the most efficient strat-
egy is to use RTX+MTX!BSC or, if the WTP of 37013
euros per QALY gained is not too much, RTX+MTX!
INFL+MTX!BSC treatment strategies after TNF-inhibi-
tor failure.
In detail, adding a second biologic treatment after
TNF-inhibitor failure increases the average treatment
costs by 16843–41866 euros and gives 0.46–0.70 addi-
tional QALYs compared with BSC alone, depending on
which biologic treatment is chosen. The most
cost-effective choice is RTX+MTX with an ICER of
30248 euros per QALY gained, which is lower than
those of either INFL+MTX (36121euros), ETAN+MTX
(50372euros), ADAL+MTX (50941euros) or ABAT+
MTX (67003euros). Treatment with RTX+MTX dominates
ETAN+MTX, ADAL+MTX and ABAT+MTX, as it is less
costly and more effective. Compared with INFL+MTX,
the cost of an additional QALY with RTX+MTX is
18585euros.
When a third biologic treatment is added after
RTX+MTX, the average treatment costs increase further
by 14024–35414 euros and result in 0.38–0.52 additional
QALYs, depending on which treatment comes next.
Compared with treatment with RTX+MTX (!BSC), the
ICERs of adding biologic treatment range from 37013
(INFL+MTX) to 68100 (ABAT+MTX) euros per QALY
gained. Compared with giving INFL+MTX as the third
biologic treatment, an additional QALY with ADAL+MTX,
ETAN+MTX and ABAT+MTX costs 260197, 145658 and
151562 euros, respectively.
In case a fourth biologic treatment is added after
INFL+MTX, the average treatment costs increase further
by 20595–34547euros and 0.38–0.49 additional QALYs
are gained. Compared with treatment with RTX+MTX!
INFL+MTX!BSC, the additional QALY with ETAN+
MTX costs 54836 euros, with ADAL+MTX 54701 euros
and with ABAT+MTX 70616 euros. Compared with
ETAN+MTX and ADAL+MTX, an additional QALY with
ABAT+MTX costs 158411 and 123 775euros, respec-
tively. Please note that ETAN+MTX and ADAL+MTX
are not compared with each other, since one of them is
assumed to have been used previously.
If the WTP for an additional QALY gained is  50000
euros, the results of the incremental cost-effectiveness
analyses performed successively for each treatment indi-
cate that the treatment succession should include only
RTX+MTX and INFL+MTX. However, if the analyses are
performed for treatment sequences (compared with BSC),
the ICERs remain <50000 euros even for those treatment
sequences that include all possible biologic treatments.
The patients in the model die shortly after their 75th
birthday. Currently, the life expectancy in Finland is 82.9
years for a newborn girl and 75.9 years for a newborn boy
[14]. When these expectancies are weighted, according to
the proportion of males and females in the model, the
obtained average life expectancy in Finland is 80.6
years. Compared with this, the patients in the model die
 5 years earlier. This is quite close to the 3–4 years
shorter life expectancy in RA patients reported in
Finland [2].
Sensitivity analyses
The robustness of the cost–utility results was tested by
performing multiple sensitivity analyses. The results of the
one-way sensitivity analyses are shown in Table 5 and
PSA is presented in Fig. 2.
TABLE 5 Results of the one-way sensitivity analyses
Change Treatment
a Cost QALYs ICER Change Treatment





BSC 83741 2.63 Negative
QALYs allowed
BSC 85724 2.37
RTX+MTX 107319 3.44 28972 RTX+MTX 106931 3.12 28302
ADAL+MTX 126046 3.46 51018 ADAL+MTX 111195 2.90 47759
ETAN+MTX 129166 3.51 51328 ETAN+MTX 112555 2.94 47114
INFL+MTX 100630 3.11 35320 INFL+MTX 102558 2.87 33710





days in all HAQ)
BSC 62153 2.69 No. of inpatient






RTX+MTX 85092 3.39 32717 RTX+MTX 92485 3.39 30197
ADAL+MTX 88877 3.19 53425 ADAL+MTX 96723 3.19 50799
ETAN+MTX 90448 3.22 53118 ETAN+MTX 98241 3.22 50553
INFL+MTX 80073 3.15 38428 INFL+MTX 88059 3.15 35911




BSC 85714 6.91 Discount rate 0% BSC 123825 3.14
RTX+MTX 106921 7.50 36228 RTX+MTX 148378 4.04 27410
ADAL+MTX 111185 7.33 60842 ADAL+MTX 151666 3.77 44491
ETAN+MTX 112546 7.36 60273 ETAN+MTX 153239 3.81 43826
INFL+MTX 102548 7.31 42794 INFL+MTX 142655 3.73 31930
ABAT+MTX 127580 7.44 79647 ABAT+MTX 170237 3.95 57578
Wholesale prices ETAN+MTX 108421 3.22 42628 RTX once in 12 months RTX+MTX 101142 3.39 22004
ADAL+MTX 107332 3.19 43218 RTX once in 6 months RTX+MTX 118470 3.39 46719
aAfter the biologic treatment, BSC is given.
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ses, the length of the average treatment period was chan-
ged to match those of a similar study by Kielhorn et al. [7].
Using these treatment lengths, the average treatment
costs of BSC are 1973 euros lower than in the base-case
scenario and 0.06 less QALYs are gained during the
remaining life time. The ICERs of this scenario do not
change dramatically from the base-case scenario (from
 3490 to 957euros). However, RTX+MTX now domi-
nates only ABAT+MTX, because ETAN+MTX and
ADAL+MTX are now both more costly and more effective
than RTX. An additional QALY with ETAN+MTX and
ADAL+MTX compared with RTX+MTX costs 306945
and 1215418 euros, whereas an additional QALY with
RTX+MTX compared with INFL+MTX now costs 19930
euros.
When the dosing interval of RTX is changed to 6 months
and 12 months, the average treatment costs increase and
decrease by 11548 and 5780 euros, respectively. With a
12-month treatment cycle of RTX, RTX+MTX dominates
all other treatments and is more effective and less costly.
With a 6-month treatment cycle of RTX, RTX+MTX dom-
inates ABAT+MTX and is more effective and more costly
than other TNF-inhibitors. An additional QALY with
RTX+MTX in this scenario costs 36209, 35169 and
67767 euros compared with ADAL+MTX, ETAN+MTX
and INFL+MTX, respectively.
Allowing the QALYs to become negative (i.e. worse
than death) decreases the QALYs gained while
costs remain the same. The cost–utility results do not
change much, because the ICERs become only  2000–
4500 euros smaller. Estimating the QoL based on
Hawthorne et al. [27] doubles the number of QALYs
gained in the model. The relative cost-effectiveness
results do not change, and RTX+MTX continues to dom-
inate ADAL+MTX, ETAN+MTX and ABAT+MTX.
However, the cost per additional QALY gained with all
treatments increases. An additional QALY with
RTX+MTX compared with INFL+MTX costs now almost
4200 euros more than in the base-case scenario (i.e.
22778 euros).
As expected, changing the discounting rate from 3 to
0% changes the results: all ICERs become clearly smaller
(by  2800–9400euros). Assuming that the number of
inpatient days is not related to the patient’s HAQ scores
(always an average 4.12 days/year) decreases the total
cost of RA treatment in this patient population. The
ICERs for all treatment alternatives compared with
BSC increase by  2000–2700 euros. Similarly, the
assumption that the number of inpatient days increases
by 10% in each HAQ category when HAQ exceeds
the value of 1.5 decreases the total treatment costs.
However, the ICERs in this case remain almost
unchanged.
The impact of the Finnish system, where wholesale
prices are used for inpatient pharmaceuticals (RTX,
ABAT and INFL) and retail prices for outpatient pharma-
ceuticals (ADAL and ETAN), was also assessed. In this
scenario, RTX+MTX still dominated both ADAL+MTX
and ETAN+MTX. However, the ICERs of ADAL+MTX
and ETAN+MTX compared with BSC dropped consider-
ably by over 7700 euros.
PSA. The CEAF approach based on PSA is depicted in
Fig. 2. According to CEAF, the optimal decision is to use
BSC with WTP levels <30246 euros per QALY gained.
RTX+MTX!BSC is the optimal decision with WTP
levels between 30249 and 37012 euros per QALY
gained. RTX+MTX!INFL+MTX!BSC becomes pref-
erable above a WTP level of 37015 euros per QALY
gained.
Furthermore, RTX+MTX!INFL+MTX!BSC becomes
a potentially cost-effective (i.e. the probability of cost-
effectiveness/highest expected net monetary benefit
FIG.2The CEAF represents the probability of cost-effectiveness of optimal treatments (i.e. treatments with the highest
expected net benefit) with different WTP levels.
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euros per QALY gained. None of the treatments achieves
potential cost-effectiveness, with WTP levels between
27961 and 44384 euros per QALY gained. However, it
should be noted that in the multiple comparison presented
in Fig. 2, the expected (default) probability of
cost-effectiveness is only 7.7% for any treatment
(i.e. actually 13 different treatment scenarios are simulta-
neously being compared in Fig. 2). With a WTP of 30000
euros per QALY gained, RTX+MTX!BSC has 37.9%
and BSC has 36.8% probability of cost-effectiveness
and with a WTP of 50000euros, RTX+MTX!INFL+
MTX!BSC 55.5% probability of cost-effectiveness;
these probabilities are significantly higher compared with
the default of 7.7% (the probabilities of cost-effectiveness
for other treatments are quite similar to or even lower than
the default). Thus, given the typical threshold of
cost-effectiveness (50000 euros per QALY gained) and
taking uncertainty into account, the optimal treatment
seems to be RTX+MTX!INFL+MTX!BSC.
Discussion
We compared the cost–utility of different treatment stra-
tegies in the treatment of severe RA after TNF-inhibitor
failure. The results indicate that RTX+MTX dominates
ADAL+MTX, ETAN+MTX and ABAT+MTX. An additional
QALY gained with RTX+MTX costs 30248 euros com-
pared with BSC and 18585euros compared with
INFL+MTX. The ICERs are 52021, 52698, 37013 and
68100euros per QALY gained for adding ADAL+MTX,
ETAN+MTX, INFL+MTX and ABAT+MTX to the
RTX+MTX strategy, respectively. According to CEAF,
only treatments with RTX+MTX or RTX+MTX followed
by INFL+MTX should be considered after TNF-inhibitor
failure, if 50000euros per QALY gained is used as a
WTP threshold. If the objective is to offer potentially
cost-effective treatment to RA patients and the threshold
is 50000 euros per QALY gained, only RTX+MTX fol-
lowed by INFL+MTX should be considered after
TNF-inhibitor failure.
According to a systematic review by Chen et al. [28], 10
economic evaluations had been published on the
cost-effectiveness of ADAL, ETAN and INFL before
February 2005. The studies included in the review
reported a large range for the values of ICERs due to
varying assumptions and parameters. The base-case
ICER was found to be around 30000pounds ( 33583
euros) per QALY gained in early RA and 50000 pounds
( 55972 euros) per QALY gained in late RA [28]. The
ICERs for late RA in the review are thus very close to
our estimates for ETAN+MTX and ADAL+MTX.
The study by Kielhorn et al. [7] is the only study thus
far reporting the cost-effectiveness of RTX in the
treatment of RA. The study reports ICERs from 11601
(12987euros) to 14690pounds (16445euros) per QALY
gained for adding RTX+MTX in two different treatment
sequences in an almost identical patient population to
ours. As the treatments included in the analyses by
Kielhorn et al. differ from ours, the comparison of the
results is not straightforward. The treatment costs in the
study by Kielhorn et al. seem to be somewhat lower than
ours (74535 euros in the secondary analysis that is similar
to our sequence, including RTX, INFL and ADAL with
costs of 141541euros). The potential reasons for these
differences cannot be analysed because the exact
resource use in Kielhorn et al. [7] is not reported.
There are some limitations that are likely to influence the
results of our study. First, the ACR response rates used in
our evaluation are mostly collected from trials whose
patient populations do not match the population of inter-
est in our study. There were no randomized, controlled
clinical trials of the efficacy of the TNF-inhibitors after
TNF-inhibitor failure. Therefore, results from trials with
TNF-inhibitor-naı ¨ve patients had to be used as estimates.
However, the response rate estimates for RTX+MTX and
ABAT+MTX match the population of interest [9, 19].
Similarly, the response rates of BSC treatments (intramus-
cular gold and CSA) had to be assumed to be identical to
MTX due to the absence of relevant reported clinical trials.
The BSC assumption, however, does not have a signifi-
cant impact on the results because the same BSC is
included in all strategies.
There is some evidence that the response rates used in
our study for TNF-inhibitors may overestimate the efficacy
of TNF-inhibitors. For example, a register-based study by
Hyrich et al. [29] showed that only 36–42% of patients
who switch their original TNF-inhibitor to another due to
inefficacy experience, an improvement of at least 0.22 U
in their HAQ scores. This improvement is even less than
that related to the ACR20 response in our study ( 0.45)
[9]. Also, the follow-up studies by Buch et al. [30] and van
der Bijl et al. [31] give similar results. For example, the
ACR20 level response was obtained by 38% of the
ETAN-treated patients with a previous treatment failure
with INFL [30] compared with the 71% estimate used in
our study. Similarly, the ACR20 level response was
obtained by 46% of ADAL patients with previous treat-
ment failure with INFL [31] compared with the 63% esti-
mate in our study. Therefore,  60% of the users of
second TNF-inhibitor may in fact be non-responders,
although the estimates used in our study are  30–40%.
Since we found no research evidence describing the
actual changes in the HAQ scores of RA patients during
the treatment periods, we had to assume that the
patients’ condition deteriorates at a certain rate during
the treatment. The rate used was 0.065 per cycle for
MTX and 0.017 for other treatments, which have also
been used in another similar study [7]. This assumption
is likely to simplify the reality, because the rate may differ
between various treatments. At least for RTX+MTX and
ABAT+MTX, the patients’ condition may even improve in
time. In studies by Keystone et al. [32] and Genovese et al.
[33], the number of patients obtaining ACR responses
increased after 6 months of treatment.
Another related factor that affects the results in our
study is the length of the average treatment period. Our
study used 3.75 years as an estimate for RTX+MTX and
ABAT+MTX and 2.5 years for TNF-inhibitors. Since there
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may well be over- or underestimates of the treatment
length in real life. The treatment length for TNF-inhibitors
in our study is based on a study by Duclos et al. [34], who
reported the treatment continuation for all TNF-inhibitor
users (regardless of product and whether it was first or
second) in one treatment centre.
According to Duclos et al. [34],  50% of TNF-inhibitor
users had discontinued to use after 2 years and 60% after
3 years. In our model, the early stoppers belong to the
non-responder group and, therefore, we increased the
length of treatment by the proportion of patients who
dropped out early (to  33 months). Since the study also
reported a hazard ratio of 2.17 for continuing the first
compared with the second treatment, we took 2.5 years
as an estimate for the treatment length. For RTX+MTX,
the treatment length was taken from a clinical trial, which
may overestimate the length of average treatment in a real
life setting. However, to keep the estimate conservative,
we did not make the assumption for RTX that patients
who discontinued early would belong to the
non-responder group (33% of patients discontinued
after the first cycle [32]). Similar treatment length to that
for RTX+MTX was assumed for ABAT+MTX. In sensitiv-
ity analyses, we took the treatment lengths from the
study by Kielhorn et al. [7]. Changing the lengths of
treatment with ETAN+MTX and ADAL+MTX did not
change the results of the analysis dramatically.
RTX+MTX no longer dominated ETAN+MTX or
ADAL+MTX, but the cost for an additional QALY gained
with ETAN+MTX and ADAL+MTX was as high as
337033–1215418 euros.
There were certain uncertainties in the evaluation of
resource use in our study. The model estimates inpatient
costs based on resource use that is determined according
to the patient’s HAQ score. Because there were no avail-
able data on this relationship for Finland, the relationship
between HAQ scores and resource use in Finland was
assumed to be identical to that in Sweden [10]. Even
though Finland and Sweden are geographically and cul-
turally very similar, there may be differences in the orga-
nization of health care. However, the differences may not
be great. According to a study by Laas et al. [20], the
resource use for patients with an average HAQ score of
1.37 in Finland was the same as that reported in the
Swedish study [10]. This assumption was also further
explored in the sensitivity analysis and was found to be
insignificant.
A further uncertainty, related to the cost estimates in our
study, is due to the fact that the outpatient costs were
not included separately in the model. This was done
to prevent potential double-counting when separate,
drug-specific administration and monitoring costs are
already in the model. The model includes the costs of
surgical procedures only to the extent that their cost is
reflected in the unit cost of an average inpatient day in
Finland. In essence, the potential differences in the need
for surgical procedures between the various treatments
are conveyed through the differences in obtained HAQ
scores, which are used to estimate the number of inpa-
tient days. The effects of surgical procedures were omit-
ted from the evaluation, since the estimation of their
benefits in terms of HAQ improvements would have
made the model extremely complex.
The base-case results of our study may not be read-
ily generalized to other countries with health care sys-
tems differing considerably from Finland. Perhaps the
biggest issue in this respect is created by the Finnish
two-tiered health care financing system, where the
pharmaceuticals given in hospital are funded by muni-
cipalities and outpatient pharmaceuticals are funded by
the Social Insurance Institution. The Finnish system
essentially leads to discrepancy in the cost structure
of outpatient and inpatient pharmaceuticals, because
a regulatory sales margin is added only to the outpa-
tient pharmaceuticals (this margin is relatively high in
Finland). The impact of this system-associated ‘distor-
tion’ was assessed in a sensitivity analysis, where the
wholesale prices were used for all products (the whole-
sale prices of pharmaceuticals in Finland are relatively
low). In this sensitivity scenario, RTX+MTX still domi-
nated ADAL+MTX and ETAN+MTX, although the
ICERs of ADAL+MTX and ETAN+MTX compared
with BSC dropped some 7700 euros. In countries
such as Sweden where the pharmacy premium (i.e.
difference between retail and wholesale price) is high
and wholesale prices are very low, these results can be
readily appealing. Also, the use of the same standard
monitoring protocol for all treatments in our evaluation
and the use of HAQ-based resource use is likely to
improve the generalization of the study results, as
long as the monitoring protocols, (relative) prices
between different biologic treatments and baseline
HAQ scores do not differ in other countries.
Last, it must be noted that the model simplifies
the actual treatment process in RA. In reality, patients
can receive the same pharmaceutical treatment again
after discontinuing it the first time. In our model, this is
not possible. However, the efficacy related to the reuse
of the same pharmaceutical may be less than in a naı ¨ve
patient and would have been very hard to capture in a
model. Patients initiating biological treatments also do
not necessarily discontinue their previous medications.
In our study, we assumed that the use of ‘golden
standard’ MTX continues. The impact of continuing
tDMARD(s) is, however, likely to be minimal as
tDMARDs are relatively cheap. In addition, the BSC
option in the model is constrained. In reality, the BSC
option is not fixed to include intramuscular gold, CSA
and MTX, but is instead tailored for each patient.
However, when modelling treatment processes, some
simplifying assumptions have to be made to prevent the
models from becoming extremely complex. If we assume
that the patients are identical with regard to their other
medications and the type of BSC suitable for them, chan-
ging these aspects in the model would not have changed
the relative results (i.e. they would equally affect all com-
pared alternatives).
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Based on current evidence, treatment with RTX followed
by BSC, and treatment with RTX followed by INFL and
BSC are the most cost-effective treatment alternatives
for Finnish patients with RA who have failed TNF-inhibitor
treatment. The efficacy estimates of TNF-inhibitors in this
study were derived from trials with TNF-inhibitor naı ¨ve
patients, and therefore the results may well overestimate
the cost-effectiveness of these products in the study
patient population compared with RTX and ABAT.
Because of this, no definite conclusions can be drawn
about the cost-effectiveness of ABAT compared with the
TNF-inhibitors.
Rheumatology key message
. RTX is a cost-effective treatment strategy in RA
after failure of TNF-inhibitor in the Finnish setting.
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